Sev­en PD-(L)1 play­ers could be vy­ing for a place on Chi­na's drug re­im­burse­ment list. How far will they go?

New up­dates to the process of as­sem­bling Chi­na’s lat­est Na­tion­al Drug Re­im­burse­ment List could mean that sev­en ad­di­tion­al PD-(L)1 drugs will be cov­ered by gov­ern­ment-spon­sored in­sur­ance schemes — but like­ly not with­out sig­nif­i­cant dis­counts.

De­vel­op­ers of ther­a­pies ap­proved by the Na­tion­al Med­ical Prod­ucts Ad­min­is­tra­tion be­fore Au­gust 17 will be el­i­gi­ble to ap­ply for in­clu­sion on the list. The dead­line al­so ap­plies to any drug that scored new in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER